OSE Immunotherapeutics - Strong momentum in deal flow
OSE Immunotherapeutic’s FY24 has started off with a series of major wins, significantly bolstering the company’s clinical pipeline and liquidity....
245 Views
OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim
OSE Immunotherapeutics has announced a considerable expansion of its partnership with Boehringer Ingelheim (BI), including the start of two new...
285 Views
OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle
OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is...
437 Views
OSE Immunotherapeutics - Funding accelerates Tedopi clinical development
Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public...
464 Views
OSE Immunotherapeutics - Pipeline momentum builds into FY24
OSE Immunotherapeutics’ (OSE’s) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal...
266 Views